Clinical Trial Update: Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with fractionated stereotactic radiotherapy for 1 to 10 brain metastases from non-small cell lung cancer has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED